Trial in progress: QUINTESSENTIAL—a phase 2 study of arlocabtagene autoleucel (arlo-cel) in patients with relapsed/refractory multiple myeloma (RRMM)
Ciara Louise Freeman(Moffitt Cancer Center), Krina K. Patel(University of Vermont), Anupama Kumar(University of California, San Francisco), Nikhil C. Munshi(Dana-Farber Cancer Institute), Susan Bal(University of Alabama at Birmingham), Tara Gregory(Colorado Blood Cancer Institute), Omar Nadeem(Harvard University), Sham Mailankody(Memorial Sloan Kettering Cancer Center), Paola Neri(University of Calgary), Hongxiang Hu(Bristol-Myers Squibb (United States)), Shinsuke Iida(Nagoya City University Hospital), Safiyyah Ziyad(Bristol-Myers Squibb (United States)), Sandy W. Wong(UCSF Helen Diller Family Comprehensive Cancer Center), Sarah Johnston(Bristol-Myers Squibb (United States)), Sarah Larson(APLA Health), Svenja Groeneveld(Bristol-Myers Squibb (United States)), Jaclyn Davis(Bristol-Myers Squibb (United States)), Julia Piasecki(Université Paris Cité), Timothy Pulham(Bristol-Myers Squibb (Sweden))
Cited by 1
Related Papers
Signatures of mutational processes in human cancer
|Nature|2013|10.1k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
Somatic<i>SF3B1</i>Mutation in Myelodysplasia with Ring Sideroblasts
|New England Journal of Medicine|2011|1.2k
Heterogeneity of genomic evolution and mutational profiles in multiple myeloma
|Nature Communications|2014|906
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma
|New England Journal of Medicine|2023|695